Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Celyad  /  Celyad 2021

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Celyad BRU:CYAD.BL, BE0974260896

  • 0,300 21 mei 2024 09:23
  • -0,018 (-5,66%) Dagrange 0,300 - 0,301
  • 15.395 Gem. (3M) 14,9K

Celyad 2021

3.900 Posts
Pagina: «« 1 ... 97 98 99 100 101 ... 195 »» | Laatste | Omlaag ↓
  2. forum rang 4 egeltjemetstekel 20 juli 2021 19:12
    Celyad Oncology ADR
    NASDAQ: CYAD
    OverviewCompareFinancials
    4,10 USD +0,040 (0,99%)today
    20 Jul, 12:50 GMT-4 · Disclaimer

    Keurige presentatie.
    Ik mis echter brekend nieuws.
    Ze boeken voortgang maar mijn indruk is dat het maar traag gaat.
    Ik wil de webcast nog nader bestuderen dat wel.

    Dit keer hadden ze een prachtig kleurrijke achtergrond.
  3. MaGu 20 juli 2021 19:57
    quote:

    egeltjemetstekel schreef op 20 juli 2021 19:12:

    Celyad Oncology ADR
    NASDAQ: CYAD
    OverviewCompareFinancials
    4,10 USD +0,040 (0,99%)today
    20 Jul, 12:50 GMT-4 · Disclaimer

    Keurige presentatie.
    Ik mis echter brekend nieuws.
    Ze boeken voortgang maar mijn indruk is dat het maar traag gaat.
    Ik wil de webcast nog nader bestuderen dat wel.

    Dit keer hadden ze een prachtig kleurrijke achtergrond.
    Mooi lettertype. Inspring op 1 lijn. Juiste lettertype. Dat werk?
  7. MaGu 20 juli 2021 20:57
    quote:

    egeltjemetstekel schreef op 20 juli 2021 20:51:

    Ja dat kan ik wel begrijpen MaGu. Maar voorlopig kun je de presentatie nog op hun website vinden om te bekijken op een moment dat je de tijd wel hebt
    Ik ga het wel terugkijken. Zie wel waar het schip strand. Eerst ga ik vanaf zaterdag heerlijk op vakantie! Ze kunnen mij wat!
  8. forum rang 4 egeltjemetstekel 20 juli 2021 22:15
    www.globenewswire.com/news-release/20...

    Celyad Oncology Presents Updates on Allogeneic CAR T Clinical Candidates and shRNA-based Preclinical Concepts at Research & Development Day
    July 20, 2021 16:01 ET
    | Source: Celyad Oncology SA

    Phase 1 IMMUNICY-1 trial evaluating CYAD-211 in relapsed/refractory multiple myeloma (r/r MM) showed dose dependent engraftment up to dose level three (300×106 cells per infusion) with no Graft-versus-Host disease reported to date
    Submission of IND application for CYAD-203, a new first-in-class shRNA-based allogeneic, IL-18-armored CAR T candidate, expected in mid-2022
    CYAD-101 following FOLFIRI preconditioning in advanced metastatic colorectal cancer (mCRC) was well-tolerated; cell kinetic and activity of alloSHRINK trial support the initiation of the KEYNOTE-B79 Phase 1b trial of CYAD-101 following FOLFOX preconditioning chemotherapy during early fourth quarter 2021
    MONT-SAINT-GUIBERT, Belgium, July 20, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Celyad Oncology or the Company), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, highlighted a new preclinical allogeneic armored CAR T candidate developed from its shRNA platform and data updates to the shRNA-based allogeneic candidate CYAD-211 for r/r MM and allogeneic candidate CYAD-101 for mCRC today during a research and development day hosted by the Company’s management team.

    “We are ushering in a new era of allogeneic CAR T candidates using novel technological advances, including our proprietary shRNA platform for allogeneic CAR T production and now the addition of our 'armored' CAR capabilities with co-expression of the cytokine IL-18," said Filippo Petti, Chief Executive Officer of Celyad Oncology. “We believe the advances we’re making may address many of the current modality limitations and have the potential to provide real-world benefits for patients, including more accessible CAR T cell treatment options, if approved. This continued technological innovation, which is currently being validated in ongoing clinical studies, establishes Celyad Oncology as a leader in this adoptive cell therapy space."

    Latest Program Updates

    CYAD-211 – Allogeneic shRNA-based, anti-BCMA CAR T for r/r MM

    CYAD-211 is the Company’s first shRNA-based allogeneic CAR T candidate, which co-expresses a BCMA targeting chimeric antigen receptor while using shRNA to knockdown expression of the CD3? component of the T-cell receptor (TCR)
    Currently, CYAD-211 is being evaluated in the Phase 1 IMMUNICY-1 trial in r/r MM following preconditioning with cyclophosphamide (300 mg/m²) and fludarabine (30 mg/m²) given three consecutive days.
    In June, preliminary data from the Phase 1 IMMUNICY-1 trial was presented at the European Hematology Association (EHA) congress demonstrating no dose limiting toxicity (DLT), Graft-versus-Host disease (GvHD) or CAR T-cell-related encephalopathy syndrome (CRES) in the first two dose levels (30×106 and 100×106 cells per infusion) of the trial. Two of the five evaluable patients at the first two dose levels achieved a partial response. In addition, CYAD-211 cells were detected by PCR-based methods in all six patients with evidence of a dose dependent increase in cell engraftment.
    Recent data from the first patient at dose level three (300×106 cells per infusion) continues to show dose dependent engraftment with no GvHD reported to date.
    Enrollment in the trial is ongoing with plans to explore higher doses of preconditioning regimens in future cohorts.
    CYAD-203 – Allogeneic shRNA-based, IL-18-armored NKG2D CAR T for Solid Tumors

    CYAD-203 is the Company’s first armored CAR T candidate engineered to co-express the cytokine interleukin-18 (IL-18) with the NKG2D CAR receptor. To the Company’s knowledge, this therapy is on track to be first ever IL-18 secreting allogeneic CAR T candidate.
    IL-18 is a proinflammatory cytokine that directly potentiates the anti-cancer activity of CAR T cells while also altering the balance of pro- and anti-inflammatory cells within tumor tissue.
    Investigational New Drug (IND)-enabling studies are currently ongoing. Submission of the IND application for CYAD-203 for treatment of solid tumors is expected in mid-2022.
    CYAD-101 – Allogeneic TIM-based NKG2D CAR T for mCRC

    To the Company’s knowledge, CYAD-101 is the first investigational allogeneic CAR T candidate to generate evidence of clinical activity for the treatment of a solid tumor indication. This is based on data from the dose-escalation segment of the alloSHRINK Phase 1 trial evaluating CYAD-101 following FOLFOX (combination of 5-fluorouracil, leucovorin and oxaliplatin) preconditioning chemotherapy for the treatment of advanced metastatic colorectal cancer (mCRC).
    Initial data from the dose expansion cohort evaluating CYAD-101 (1×109 cells per infusion) following FOLFIRI (combination of 5-fluorouracil, leucovorin and irinotecan) preconditioning chemotherapy showed CYAD-101 was generally well-tolerated with no dose limiting toxicities or evidence of GvHD. Overall, nine out of ten evaluable mCRC patients showed stable disease at first tumor assessment.
    Data also showed shorter persistence of CYAD-101 cells observed after FOLFIRI preconditioning as compared to FOLFOX preconditioning. Based on better CYAD-101 cell kinetics and clinical activity data from the alloSHRINK FOLFOX cohort, the Company submitted a protocol amendment to regulatory agencies to modify the Phase 1b KEYNOTE-B79 trial to incorporate FOLFOX as preconditioning chemotherapy.
    The KEYNOTE-B79 trial to evaluate CYAD-101 with Merck’s anti-PD­1 therapy, KEYTRUDA® (pembrolizumab), in refractory mCRC patients with microsatellite stable / mismatch-repair proficient disease is expected to be initiated during the fourth quarter of 2021.
    Business Update

    Celyad Oncology has acquired an exclusive license from the Moffitt Cancer Center for an antibody directed to Tumor-associated glycoprotein (TAG-72), which will form the basis of a T cell engager to be used with our proprietary shRNA platform technology. TAG-72 has been shown to be expressed in a wide variety of epithelial malignant tissues including breast, colon and pancreatic cells and will expand the Company’s program portfolio in solid tumor targets.
    Upcoming Milestones

    Additional clinical activity data for the Phase 1 IMMUNICY-1 trial of CYAD-211 for r/r MM are expected during second half 2021.
    Study initiation for KEYNOTE-B79 Phase 1b is expected early fourth quarter 2021.
    Submission of an IND application for CYAD-203 is expected in mid-2022.
    Report additional data from the dose-escalation Phase 1 CYCLE-1 trial evaluating CYAD-02 in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome in mid-2021.
    About Celyad Oncology

    Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com.
  19. p/o 21 juli 2021 20:04
    Koers tikte vandaag in de States 4.62 aan = 3.92 euro
    Aangezien we in Europa altijd hoger stonden zou een koers van 4 morgen me niet verbazen.

    3,78 60 1

    3,845 60 1

    3,85 2.056 1

    3,9 18 1

    3,95 75 1

    3,98 373 1

    3,99 340 1

    4 1.966 4

    4,18 500 1

    4,2 524 1

    en dan laten ze hun pr machine hopelijk eens verder draaien.

    In die voorstelling was het allemaal goed nieuws nu willen we resultaten zien.
    We zijn lang genoeg op de proef gesteld.
3.900 Posts
Pagina: «« 1 ... 97 98 99 100 101 ... 195 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!